Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

19.63USD
20 Jul 2018
Change (% chg)

$-0.42 (-2.09%)
Prev Close
$20.05
Open
$20.05
Day's High
$20.19
Day's Low
$19.50
Volume
64,618
Avg. Vol
286,553
52-wk High
$25.20
52-wk Low
$8.36

Chart for

About

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The... (more)

Overall

Beta: 3.73
Market Cap(Mil.): $967.78
Shares Outstanding(Mil.): 48.29
Dividend: --
Yield (%): --

Financials

  OMER.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -1.45 -- --
ROI: -129.34 -3.67 13.17
ROE: -- -5.61 15.10

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING

May 24 2018

BRIEF-Omeros Corporation Q1 Loss Per Share $0.62

* Q1 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROS’ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

Apr 26 2018

BRIEF-Omeros Announces Amendment Of Credit Facility

* AMENDED ITS EXISTING CREDIT FACILITY WITH CERTAIN AFFILIATES OF CRG LP

Apr 11 2018

BRIEF-Omeros Q4 Loss Per Share $0.34

* Q4 REVENUE $13.8 MILLION Source text for Eikon: Further company coverage:

Mar 01 2018

BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721

* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY

Jan 22 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.85 -0.09
Novartis AG (NOVN.S) CHF82.20 +1.24
Pfizer Inc. (PFE.N) $37.33 -0.03
Roche Holding Ltd. (ROG.S) CHF234.00 +2.05
Roche Holding Ltd. (RO.S) CHF238.60 +2.80
Merck & Co., Inc. (MRK.N) $62.52 +0.01
Bayer AG (BAYGn.DE) €92.05 -0.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €72.36 +0.25
Eli Lilly And Co (LLY.N) $88.47 -0.96

Earnings vs. Estimates